Share this article
Share this article
NEW YORK, July 22, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ( CorMedix or the Company ) (NASDAQ: CRMD) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-14020, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CorMedix securities between July 8, 2020 and May 13, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
District Court Grants Stay Of Recently-Filed Infringement Suit In Favor Of TTAB Proceeding Nearing Completion - Intellectual Property
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
ParkerVision Receives Second Favorable Markman Ruling in ParkerVision v Intel
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
If you purchased certain microcap stock between May 2016 and July 2019, you may be eligible for distribution from the O Rourke Distribution Fund
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Daniel Schnapp Reflects on Crucial Court Judgment Involving the Inverse Ratio Rule
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.